Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

The drug, amitriptyline, is a tricyclic antidepressants used in the treatment of various health conditions such as chronic neuropathic pain, depression, and others. The drug is also used off-label in treatment of migraine. Amitriptyline affects certain chemical messengers (neurotransmitters) that communicate between brain cells and help regulate mood. The drug is also available in combinations such as Anxipan (amitriptyline and pantoprazole) and Limbitrol Tablet (amitriptyline and chlordiazepoxide).

The global amitriptyline market is estimated to be valued at US$ 527.4 million in 2020 and is expected to exhibit a CAGR of 5.3% during the forecast period (2020-2027).

Figure 1. Global Amitriptyline Market Share (%), by Indication, 2020

Amitriptyline  | Coherent Market Insights

Global Amitriptyline Market: Driver

Rising concerns about neuropathic pain, migraine, and related disorders are expected to drive demand for amitriptyline and favor growth of the global amitriptyline market. According to clinical evaluation study published in National Center for Biotechnology Information (NCBI) 2010, the estimated community prevalence of neuropathic pain from the clinical examination (gold standard) was 9.8%. The condition is more prevalent among the elderly population.

Moreover, amitriptyline is an effective, off-label, and inexpensive agent that is useful for prevention of migraine, and tension-type headache. According to Migraine Research Foundation, migraine is the third most common disease in the world, and has affected 39 million men, women and children in the U.S. and 1 billion worldwide in 2019.

request-sample

Amitriptyline Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 527.4 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 5.3% 2027 Value Projection: US$ 762.2 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of the Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Strength: 10 mg tablets, 25 mg tablets, 50mg tablets, 75 mg tablets, 100 mg tablets, 150 mg tablets.
  • By Indication: Depression, Nocturnal Enuresis, Migraine, Chronic Neuropathic Pain, Others.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Sandoz Inc., Sun Pharmaceutical Industries Inc., Vintage Pharmaceuticals Inc., Zydus Pharmaceuticals USA Inc., Watson laboratories Inc., and Torrent Pharmaceuticals Ltd.

Growth Drivers:
  • Strong product pipeline
  • Increasing prevalence of neuropathic pain and migraine
Restraints & Challenges:
  • Side effects associated with amitriptyline

Global Amitriptyline Market: Restraint

Intolerable side effects of amitriptyline are expected to affect demand for the drug. The side effects of amitriptyline include nausea, vomiting, drowsiness, weakness or tiredness, nightmares, headaches, dry mouth, constipation, changes in sex drive and others. Thus, side effects associated with the drug can shift patient’s preference to alternative treatments. Such factors are expected to hamper the growth of the market.

Figure 2. Global Amitriptyline Market Value (US$ Mn), by Region, 2020

Amitriptyline  | Coherent Market Insights

The North America amitriptyline market is expected to exhibit significant growth during the forecast period owing to the increasing prevalence of neuropathic pain among the U.S. population. According to a study published in the Journal of Pain Research, in 2018, the reported prevalence of neuropathic pain in the U.S. was 10%. The National Institute of Neurological Disorders and Stroke (NINDS) reported that 20 million Americans have some type of peripheral neuropathy.

Key Players

Major players operating in the global amitriptyline market are Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Sandoz Inc., Sun Pharmaceutical Industries Inc., Vintage Pharmaceuticals Inc., Zydus Pharmaceuticals USA Inc., Watson laboratories Inc., and Torrent Pharmaceuticals Ltd.

Amitriptyline is a tricyclic antidepressant with sedative effects. Amitriptyline affects certain chemical messengers (neurotransmitters) that communicate between brain cells and help to regulate the mood. The drug is indicated for treatment of major depressive disorder, neuropathic pain, the prophylactic treatment of chronic tension type headache (CTTH) and migraine in adults, also used in the treatment of nocturnal enuresis. It is available in tablet form.

Market Dynamics

Increasing prevalence of depression or bipolar disorder is expected to drive demand for tricyclic antidepressants such as Amitriptyline, thereby contributing to growth of the global amitriptyline market. According to the Global Burden of Disease Collaborative Network, in 2017, the prevalence of bipolar disorder ranged from 0.3% to 1.2% by country, and around 46 million people suffered from the bipolar disorder worldwide. Bipolar disorder is a brain disorder, also known as manic illness, which affects the mood, energy level, and other activities.

Key features of the study:

  • This report provides in-depth analysis of the global amitriptyline market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global amitriptyline market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Sandoz Inc., Sun Pharmaceutical Industries Inc., Vintage Pharmaceuticals Inc., Zydus Pharmaceuticals USA Inc., Watson laboratories Inc., and Torrent Pharmaceuticals Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global amitriptyline market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurofibromatosis treatment drugs market.

Detailed Segmentation:

  • Global Amitriptyline Market, By Strength:
    • 10 mg tablets
    • 25 mg tablets
    • 50 mg tablets
    • 75 mg tablets
    • 100 mg tablets
    • 150 mg tablets
  • Global Amitriptyline Market, By Indication:
    • Depression
    • Nocturnal Enuresis
    • Migraine
    • Chronic Neuropathic Pain
    • Others
  • Global Amitriptyline Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Amitriptyline Market, By Region:
    • North America
      • By Strength:
        • 10 mg tablets
        • 25 mg tablets
        • 50 mg tablets
        • 75 mg tablets
        • 100 mg tablets
        • 150 mg tablets
      • By Indication:
        • Depression
        • Nocturnal Enuresis
        • Migraine
        • Chronic Neuropathic Pain
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Strength:
        • 10 mg tablets
        • 25 mg tablets
        • 50 mg tablets
        • 75 mg tablets
        • 100 mg tablets
        • 150 mg tablets
      • By Indication:
        • Depression
        • Nocturnal Enuresis
        • Migraine
        • Chronic Neuropathic Pain
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Strength:
        • 10 mg tablets
        • 25 mg tablets
        • 50 mg tablets
        • 75 mg tablets
        • 100 mg tablets
        • 150 mg tablets
      • By Indication:
        • Depression
        • Nocturnal Enuresis
        • Migraine
        • Chronic Neuropathic Pain
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Strength:
        • 10 mg tablets
        • 25 mg tablets
        • 50 mg tablets
        • 75 mg tablets
        • 100 mg tablets
        • 150 mg tablets
      • By Indication:
        • Depression
        • Nocturnal Enuresis
        • Migraine
        • Chronic Neuropathic Pain
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Strength:
        • 10 mg tablets
        • 25 mg tablets
        • 50 mg tablets
        • 75 mg tablets
        • 100 mg tablets
        • 150 mg tablets
      • By Indication:
        • Depression
        • Nocturnal Enuresis
        • Migraine
        • Chronic Neuropathic Pain
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Strength:
        • 10 mg tablets
        • 25 mg tablets
        • 50 mg tablets
        • 75 mg tablets
        • 100 mg tablets
        • 150 mg tablets
      • By Indication:
        • Depression
        • Nocturnal Enuresis
        • Migraine
        • Chronic Neuropathic Pain
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Accord Healthcare Inc.*
      • Company Overview
      • Strength Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Mylan Pharmaceuticals Inc.
    • Sandoz Inc.
    • Sun Pharmaceutical Industries Inc.
    • Vintage Pharmaceuticals Inc.
    • Zydus Pharmaceuticals USA Inc.
    • Watson laboratories Inc.
    • Torrent Pharmaceuticals Ltd.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Strength
      • Market Snippet, By Indication
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Impact Analysis
    • Market Opportunities
    • Collaborations and Acquisition
    • Regulatory Scenario
  4. Global Amitriptyline Market, Impact of COVID-19 Pandemic
    • During COVID-19 Impact
    • Post COVID-19 Impact
    • Government Initiatives
    • Overall Impact On the Healthcare Industry
  5. Global Amitriptyline Market, By Strength, 2016-2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
        • Segment Trends
          • 10 mg tablets
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
          • 25 mg tablets  
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
          • 50 mg tablets
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
          • 75 mg tablets
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
          • 100 mg tablets
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
          • 150 mg tablets
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  6. Global Amitriptyline Market, By Indication, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
        • Segment Trends
          • Depression
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
          • Nocturnal Enuresis
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
          • Migraine
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
          • Chronic Neuropathic Pain
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
          • Others
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
  7. Global Amitriptyline Market, By Distribution Channel, 2020 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017– 2027
        • Segment Trends
          • Hospital Pharmacies
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
          • Retail Pharmacies
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
          • Online Pharmacies
            • Introduction
            • Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
  8. Global Amitriptyline Market, By Region, 2016–2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Country, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Countries, 2017–2027
    • North America
      • Introduction
      • Market Size and Forecast, By Strength, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Indication, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel  , 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, By Strength, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Indication, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, By Strength, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Indication, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, By Strength, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Indication, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, By Strength, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Indication, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2027 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, By Strength, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Indication, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2027 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016–2027 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Company Profiles
      • Accord Healthcare Inc.*
        • Company Overview
        • Strength Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Mylan Pharmaceuticals Inc.
        • Company Overview
        • Strength Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sandoz Inc.
        • Company Overview
        • Strength Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sun Pharmaceutical Industries Inc.
        • Company Overview
        • Strength Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Vintage Pharmaceuticals Inc.
        • Company Overview
        • Strength Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Zydus Pharmaceuticals USA Inc.
        • Company Overview
        • Strength Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Watson laboratories Inc.
        • Company Overview
        • Strength Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Torrent Pharmaceuticals Ltd.
        • Company Overview
        • Strength Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies

*Browse 36 market data tables and 37 figures on "Global Amitriptyline Market– Global forecast to 2027”.

Frequently Asked Questions

The global amitriptyline market size is estimated to be valued at US$ 762.2 million in 2020 and is expected to exhibit a CAGR of 5.3% between 2020 and 2027.
Strong product pipeline and increasing prevalence of neuropathic pain are driving growth of the global amitriptyline market.
10mg is the leading disease type segment in global amitriptyline market and is estimated to hold major market share in 2020, owing to increasing number of drug trials and approvals.
Chronic neuropathic pain is the leading drug strength segment in the global amitriptyline market and is estimated to hold major market share in 2020, owing to increasing number of product launches
North America is the leading region in the global amitriptyline market and estimated to generate highest revenue share in 2020.
Side effects associated with amitriptyline are expected to hamper growth of the market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner